1. Home
  2. TRTX vs MNMD Comparison

TRTX vs MNMD Comparison

Compare TRTX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$9.16

Market Cap

708.3M

Sector

Real Estate

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$12.61

Market Cap

960.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRTX
MNMD
Founded
2014
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
708.3M
960.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
TRTX
MNMD
Price
$9.16
$12.61
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$10.75
$25.78
AVG Volume (30 Days)
516.7K
1.5M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
10.48%
N/A
EPS Growth
N/A
N/A
EPS
0.65
N/A
Revenue
$138,590,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.19
N/A
P/E Ratio
$14.14
N/A
Revenue Growth
4.13
N/A
52 Week Low
$6.47
$4.70
52 Week High
$9.85
$14.43

Technical Indicators

Market Signals
Indicator
TRTX
MNMD
Relative Strength Index (RSI) 59.61 55.67
Support Level $9.01 $12.19
Resistance Level $9.17 $13.45
Average True Range (ATR) 0.14 0.70
MACD 0.01 0.08
Stochastic Oscillator 87.00 72.07

Price Performance

Historical Comparison
TRTX
MNMD

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: